Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 7/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 3/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18314432 | 0.98 | SMPD1 (0.60) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2353533 | 0.88 | RARB (0.64) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL903875 | 0.88 | SMPD1 (0.61) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL7403884 | 0.88 | RARB (0.64) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL12243181 | 0.87 | SMPD1 (0.60) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2354881 | 0.87 | RARB (0.67) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL12243188 | 0.87 | SMPD1 (0.60) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL12243204 | 0.87 | SMPD1 (0.60) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL5148937 | 0.87 | RARB (0.63) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL16217721 | 0.87 | SMPD1 (0.60) | SMPD1CYP1A2CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016479-B2 | Dosing regimens for echinocandin class compounds | CIDARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016479-B2 | Dosing regimens for echinocandin class compounds | CIDARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170151306-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | NAPP PHARMACEUTICAL GROUP LIMITED (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20170151306-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | NAPP PHARMACEUTICAL GROUP LIMITED (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20120190613-A1 | ECHINOCANDIN DERIVATIVES | JAMES JR KENNETH DUKE (US) | 2012-07-26 | — | — | US | disclosed |
| US-7902148-B2 | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent | THERAVANCE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2011025875-A1 | ECHINOCANDIN DERIVATIVES | SEACHAID PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20090221470-A1 | USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT | CUMBERLAND PHARMACEUTICALS INC. | 2009-09-03 | — | — | US | disclosed |
| US-7452861-B2 | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent | THERAVANCE, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016479-B2 | Dosing regimens for echinocandin class compounds | XPO5, XPO1, CYP3A5 | SMPD1 2273/4885CYP1A2 98/4885CYP19A1 636/4885 |
| US-20170151306-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | XPO5, XPO1, CYP3A5 | SMPD1 2273/4885CYP1A2 98/4885CYP19A1 636/4885 |
| US-20120190613-A1 | ECHINOCANDIN DERIVATIVES | ERG28, DPM1, EML4 | SMPD1 532/4885CYP1A2 78/4885CYP19A1 1189/4885 |
| US-20090221470-A1 | USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT | DPM1, ERG28, ENGASE | SMPD1 2032/4885CYP1A2 2774/4885CYP19A1 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.